Treatment of sarcoidosis using placental stem cells

Abstract

Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.

1 . A method of treating an individual having sarcoidosis comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said sarcoidosis, and wherein said sarcoidosis is not pulmonary sarcoidosis. 
     
     
         2 . The method of  claim 1 , wherein said placental stem cells are CD10 + , CD34 − , CD105 + , CD200 +  placental stem cells. 
     
     
         3 . The method of  claim 2 , wherein said placental stem cells are additionally CD45 −  or CD90 + . 
     
     
         4 . The method of  claim 2 , wherein said placental stem cells are additionally one or more of CD38 − , CD45 − , CD80 − , CD86 − , CD133 − , HLA-DR,DP,DQ − , SSEA3 − , SSEA4 − , CD29 + , CD44 + , CD73 + , CD90 + , HLA-A,B,C + , PDL1 + , ABC-p + , or OCT-4 + . 
     
     
         5 . The method of  claim 2 , wherein said placental stem cells are additionally one or more of CD29 + , CD38 − , CD44 + , CD54 + , SH3 +  or SH4 + . 
     
     
         6 . The method of  claim 2 , wherein said placental stem cells are additionally CD44 + . 
     
     
         7 . The method of  claim 1 , wherein said placental stem cells express CD200 and do not express HLA-G, or express CD73. CD105, and CD200, or express CD200 and OCT-4, or express CD73 and CD105 and do not express HLA-G, or express CD73 and CD105 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body, or express OCT-4 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body. 
     
     
         8 - 23 . (canceled) 
     
     
         24 . The method of  claim 1 , comprising administering a second therapeutic agent to said individual. 
     
     
         25 . The method of  claim 24 , wherein said second therapeutic agent is an anti-inflammatory agent, a steroid, an immunosuppressant compound, or an antibiotic.